Potrero Capital Research LLC Makes New Investment in Grail, Inc. (NASDAQ:GRAL)

Potrero Capital Research LLC acquired a new stake in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 364,949 shares of the company's stock, valued at approximately $6,514,000. Grail accounts for 2.2% of Potrero Capital Research LLC's portfolio, making the stock its 14th biggest holding. Potrero Capital Research LLC owned 1.09% of Grail as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Crcm LP bought a new position in shares of Grail during the 4th quarter worth $65,061,000. Primecap Management Co. CA purchased a new stake in Grail in the fourth quarter worth about $37,118,000. Baker BROS. Advisors LP purchased a new stake in Grail in the fourth quarter worth about $29,098,000. Vanguard Group Inc. bought a new position in Grail during the 4th quarter worth about $25,902,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Grail during the 4th quarter valued at about $18,209,000.

Grail Price Performance

Shares of GRAL stock traded up $2.12 during mid-day trading on Tuesday, hitting $40.35. 432,577 shares of the stock traded hands, compared to its average volume of 1,255,633. The stock's fifty day moving average is $30.16 and its two-hundred day moving average is $26.92. Grail, Inc. has a 52-week low of $12.33 and a 52-week high of $63.99. The stock has a market cap of $1.45 billion and a P/E ratio of -0.66.

Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.03) by $0.93. The firm had revenue of $31.84 million during the quarter, compared to analysts' expectations of $35.80 million. As a group, equities analysts forecast that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on GRAL shares. Canaccord Genuity Group upped their price target on shares of Grail from $32.00 to $43.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Morgan Stanley upped their target price on Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a report on Tuesday, March 18th.

Insider Activity at Grail

In other news, CFO Aaron Freidin sold 1,816 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $56,659.20. Following the sale, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at $10,457,304. The trade was a 0.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Joshua J. Ofman sold 2,109 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $65,800.80. Following the completion of the transaction, the president now owns 559,673 shares of the company's stock, valued at $17,461,797.60. This trade represents a 0.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 194,948 shares of company stock valued at $6,583,130 in the last ninety days. Corporate insiders own 1.85% of the company's stock.

About Grail

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.